Antitumor immune response is associated with favorable survival in GEP-NEN G3. Issue 10 (2nd September 2021)
- Record Type:
- Journal Article
- Title:
- Antitumor immune response is associated with favorable survival in GEP-NEN G3. Issue 10 (2nd September 2021)
- Main Title:
- Antitumor immune response is associated with favorable survival in GEP-NEN G3
- Authors:
- Rosery, Vivian
Reis, Henning
Savvatakis, Konstantinos
Kowall, Bernd
Stuschke, Martin
Paul, Andreas
Dechêne, Alexander
Yang, JiaJin
Zhao, Ben
Borgers, Arianna
Kasper, Stefan
Schuler, Martin
Cheung, Phyllis F
Siveke, Jens T - Abstract:
- Abstract : The tumor immune microenvironment (TME) represents a key determinant for responses to cancer treatment. However, the immune phenotype of highly proliferative gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is still largely elusive. In this retrospective study, we characterized the TME of high-grade (G3, Ki-67 > 20%) GEP-NEN. We analyzed formalin-fixed paraffin-embedded samples from 37 patients with GEP-NEN G3 by immunohistochemistry and multiplex immunofluorescence to address the abundance and spatial interaction of relevant immune subsets. We focused on the expression of immune checkpoint molecules PD-1 and PD-L1, the cytotoxic T-cell marker CD8, and the tumor-associated macrophage marker CD206. Findings were correlated with overall survival (OS) from the date of a cancer diagnosis. Patients with PD-L1-positive tumors (CPS ≥ 1) and intense PD-1 + CD8 + immune cell infiltration showed the most favorable median OS. Multiplex immunofluorescence staining of ten representative tissue samples illustrated intratumoral heterogeneity of PD-L1 expression. Dense PD-1 + CD8 + immune cell infiltrates were observed in PD-L1-positive tumor regions but not in PD-L1-negative regions. Proximity analysis revealed a spatial interaction between PD-1 + CD8 + cells and PD-L1-positive cells. Our data suggest a pre-existing antitumor immune response in the TME in a subgroup of GEP-NEN G3. This supports a targeted clinical exploration of immunotherapeutic approaches.
- Is Part Of:
- Endocrine-related cancer. Volume 28:Issue 10(2021)
- Journal:
- Endocrine-related cancer
- Issue:
- Volume 28:Issue 10(2021)
- Issue Display:
- Volume 28, Issue 10 (2021)
- Year:
- 2021
- Volume:
- 28
- Issue:
- 10
- Issue Sort Value:
- 2021-0028-0010-0000
- Page Start:
- 683
- Page End:
- 693
- Publication Date:
- 2021-09-02
- Subjects:
- PD-1 -- PD-L1 -- checkpoint molecule -- immune infiltrate -- spatial imaging -- gastroenteropancreatic neuroendocrine neoplasm
Endocrine glands -- Cancer -- Periodicals
Endocrinology -- Periodicals
Cancer -- Endocrine aspects -- Periodicals
616.9944005 - Journal URLs:
- http://www.bioscientifica.com/ ↗
http://erc.endocrinology-journals.org/ ↗ - DOI:
- 10.1530/ERC-21-0223 ↗
- Languages:
- English
- ISSNs:
- 1351-0088
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20679.xml